Recruiting
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
J2G-MC-JZJB - ClinicalTrials.gov - NCT04211337
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last approximately 30 months, depending on your cancer type and how you and your tumor respond.
Recruiting
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
J2G-MC-JZJB - ClinicalTrials.gov - NCT04211337
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last approximately 30 months, depending on your cancer type and how you and your tumor respond.
Key Requirements
Age :
12+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
12+
Sex
All
Participants must
Participants must have medullary thyroid cancer that is not able to be removed by surgery or has spread to other places in the body, has not been treated with certain medications previously, and has evidence on imaging studies that the cancer has gotten bigger in the previous 14 months
Participants must have evidence that their cancer is caused by a mutation in the RET gene
Participants must be in fair to good general health and not have another serious medical condition
Participants must be willing to use highly effective contraception during the study
Participants must NOT
Participants must not have cancer that has spread to the brain or spinal cord that is causing symptoms
Participants must not have a heart condition that puts you at risk for abnormal heart rhythms
Trial Summary
Conditions the trial is for
Head and Neck Cancer, Pediatric Solid Tumors, Thyroid Cancer, Pediatric Cancer
What the trial is testing?
Selpercatinib, Cabozantinib, Vandetanib
Could I receive a Placebo?
no
Enrollment Goal
400
Trial Dates
February 2020 - November 2026
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
12+
Sex
All
Participants must
Participants must have medullary thyroid cancer that is not able to be removed by surgery or has spread to other places in the body, has not been treated with certain medications previously, and has evidence on imaging studies that the cancer has gotten bigger in the previous 14 months
Participants must have evidence that their cancer is caused by a mutation in the RET gene
Participants must be in fair to good general health and not have another serious medical condition
Participants must be willing to use highly effective contraception during the study
Participants must NOT
Participants must not have cancer that has spread to the brain or spinal cord that is causing symptoms
Participants must not have a heart condition that puts you at risk for abnormal heart rhythms
Trial Summary
Conditions the trial is for
Head and Neck Cancer, Pediatric Solid Tumors, Thyroid Cancer, Pediatric Cancer
What the trial is testing?
Selpercatinib, Cabozantinib, Vandetanib
Could I receive a Placebo?
no
Enrollment Goal
400
Trial Dates
February 2020 - November 2026
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
